Quarterly ResultMay 7, 2026, 04:20 PM
Stevanato Group Q1 Revenue +7% to 273.6M; Maintains 2026 Guidance
AI Summary
Stevanato Group reported a solid start to fiscal 2026 with Q1 revenue increasing 7% to 273.6 million, or 10% at constant currency. The Biopharmaceutical and Diagnostic Solutions (BDS) Segment showed strong growth, offsetting a decline in the Engineering Segment. The company also improved its adjusted EBITDA margin by 150 basis points to 23.9% and reaffirmed its full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted diluted EPS.
Key Highlights
- Q1 2026 revenue increased 7% (10% at constant currency) to 273.6 million.
- Adjusted EBITDA margin increased 150 basis points to 23.9% in Q1 2026.
- Diluted earnings per share were 0.10, and adjusted diluted EPS were 0.11 for Q1 2026.
- Biopharmaceutical and Diagnostic Solutions (BDS) Segment revenue grew 13% (16% at constant currency) to 249.0 million.
- Engineering Segment revenue decreased 31% to 24.6 million in Q1 2026.
- High-value solutions revenue increased 17% to 128.6 million, representing 47% of total revenue.
- Company maintains fiscal 2026 revenue guidance of 1.26 billion to 1.29 billion.
- Company maintains fiscal 2026 adjusted diluted EPS guidance of 0.59 to 0.63.